Premium
Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti‐tubercular treatment
Author(s) -
Bartoletti Michele,
Martelli Giulia,
Tedeschi Sara,
Morelli Mariacristina,
Bertuzzo Valentine,
Tadolini Marina,
Pianta Paolo,
Cristini Francesco,
Giannella Maddalena,
Lewis Russell E.,
Pinna Antonio D.,
Viale Pierluigi
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12658
Subject(s) - medicine , contraindication , ethambutol , concomitant , liver transplantation , tuberculosis , isoniazid , surgery , gastroenterology , transplantation , pathology , alternative medicine
Background Active tuberculosis ( TB ) is commonly considered a contraindication for liver transplantation ( LT ). However, in patients with TB who develop acute liver failure ( ALF ) due to toxicity induced by anti‐tubercular treatment ( ATT ), LT could be the only opportunity for treatment. The aim of this study was to evaluate the feasibility of LT in this scenario. Methods We described 2 cases and comprehensively reviewed the literature finding 26 cases of LT performed in patients having a concomitant active TB and liver failure secondary to ATT toxicity. Results TB was classified as pulmonary in 18/26 (69%), nodal in 3/26 (11%) TB cases, while the remaining 5/26 cases included disseminated, pleural, renal, ovarian, and vertebral TB localization (1 case each). ATT following LT consisted mainly of isoniazid or rifampin ( RIF )‐sparing regimens and included primarily fluoroquinolones and ethambutol. Rejection episodes and liver toxicity were reported in 19% and 8% of patients respectively. Graft rejection was more frequent among patients treated with RIF ‐containing regimens ( P <.001). Mortality rate was 15% after a median follow up of 12 months. In only one case was death attributed to uncontrolled TB infection. Conclusion Our findings suggest that LT is an effective therapeutic option for patients with active TB developing ALF following ATT and should be considered for patients failing medical treatment.